Patient characteristics at maintenance randomization
| Characteristic . | Maintenance regimen . | |
|---|---|---|
| Prednisone, 10 mg (n = 65) . | Prednisone, 50 mg (n = 61) . | |
| Median age, y (range) | 61 (35-81) | 63 (41-79) |
| Sex, male/female | 37/28 (57%/43%) | 38/23 (62%/38%) |
| Race, white/black/ Hispanic/other | 49/12/3/1 (75%/18%/5%/2%) | 47/9/3/2 (77%/15%/5%/3%) |
| Induction regimen | ||
| VAD-P | 31 (48%) | 33 (54%) |
| VAD-P/Q | 34 (52%) | 28 (46%) |
| Response to induction | ||
| 25%-49% reduction | 4 (6%) | 3 (5%) |
| 50%-74% reduction | 16 (25%) | 12 (20%) |
| 75%-100% reduction | 45 (69%) | 46 (75%) |
| Serum albumin, at least 3 g/dL | 98% | 94% |
| Serum calcium, less than 12 mg/dL | 100% | 100% |
| Serum creatinine, less than 2 mg/dL | 90% | 94% |
| Serum β2-M, less than 6 μg/mL | 91% | 95% |
| Maximum grade any toxicity on maintenance therapy | ||
| At most Grade 2 | 79% | 75% |
| Grade 3-5 | 21% | 25% |
| Characteristic . | Maintenance regimen . | |
|---|---|---|
| Prednisone, 10 mg (n = 65) . | Prednisone, 50 mg (n = 61) . | |
| Median age, y (range) | 61 (35-81) | 63 (41-79) |
| Sex, male/female | 37/28 (57%/43%) | 38/23 (62%/38%) |
| Race, white/black/ Hispanic/other | 49/12/3/1 (75%/18%/5%/2%) | 47/9/3/2 (77%/15%/5%/3%) |
| Induction regimen | ||
| VAD-P | 31 (48%) | 33 (54%) |
| VAD-P/Q | 34 (52%) | 28 (46%) |
| Response to induction | ||
| 25%-49% reduction | 4 (6%) | 3 (5%) |
| 50%-74% reduction | 16 (25%) | 12 (20%) |
| 75%-100% reduction | 45 (69%) | 46 (75%) |
| Serum albumin, at least 3 g/dL | 98% | 94% |
| Serum calcium, less than 12 mg/dL | 100% | 100% |
| Serum creatinine, less than 2 mg/dL | 90% | 94% |
| Serum β2-M, less than 6 μg/mL | 91% | 95% |
| Maximum grade any toxicity on maintenance therapy | ||
| At most Grade 2 | 79% | 75% |
| Grade 3-5 | 21% | 25% |
See Table 1 for abbreviations.